Stock Code
688488.SH
EN
/
CN
About Aidea
About Aidea
Company Profile
Leadership Team
Science & Drug
Science & Drug
R&D Innovation
Product Center
Product Pipeline
Academic Achievements
News Center
News Center
Aidea News
Aidea Milestones
International Business
Career Development
About Aidea
Company Profile
Leadership Team
Science & Drug
R&D Innovation
Product Center
Product Pipeline
Academic Achievements
News Center
Aidea News
Aidea Milestones
International Business
Career Development
Product Pipeline
Home
>
Science & Drug
>
Product Pipeline
R&D Innovation
Product Center
Product Pipeline
Academic Achievements
Product Pipeline
Aibangde
®
- ACC007
HIV infection
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
Aitribond
®
- ACC008
HIV infection (treatment-experienced patients)
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
Aitribond
®
- ACC008
HIV infection (treatment-naïve patients)
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
Aitribond
®
- ACC008
HIV infection
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
ACC017 (China)
HIV infection
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
ACC017 (America)
HIV infection
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
ADC118 (China)
HIV infection
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
ADC118 (America)
HIV infection
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
ACC085
HIV pre-exposure prophylaxis (PrEP)
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
ACC077
HIV pre-exposure prophylaxis (PrEP)
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
ADC205
HIV infection
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
Dolutegravir Sodium Tablets - ADC201
HIV infection
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
Darunavir Tablets - ADC202
HIV infection
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
Human-derived Protein Pipeline
AD108
Stroke
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
ADB116
Stroke
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
AD105
Anti-inflammatory
Preclinical
IND Application
Phase I
Phase II
Phase III
NDA Application
Marketed
Note: Project data and progress as of the end of Q1 2026
